ESR1 and breast carcinoma: While these previous studies evaluated LRR risk by receptor status, this NMA has the advantage of solely quantifying LRR risk using the 21-gene expression assay in ER+/HER2− disease, highlighting the value of genomic testing in estimating LRR rates in this subgroup of breast carcinoma.